COMMUNIQUÉS West-GlobeNewswire
-
H1 Launches Site Network Suite, the First AI-Powered Platform to Transform How Research Sites and Sponsors Engage on Clinical Trials
23/04/2026 -
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio
23/04/2026 -
SS Innovations Unveils Cutting-Edge Surgical Robotic Technologies at SMRSC 2026
23/04/2026 -
Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications
23/04/2026 -
ICU Medical Announces Time of First Quarter 2026 Earnings Conference Call
23/04/2026 -
Ritedose, University of South Carolina Welcome Top European Business Students for Immersive Learning about Advanced Manufacturing
23/04/2026 -
Noom Health’s SmartRx Program on Track to Cut Employer’s GLP-1 Spend by Nearly 80%
23/04/2026 -
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
23/04/2026 -
Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026
23/04/2026 -
Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026
23/04/2026 -
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Real-World Example of Scientific Advancement Influence on Evaluation
23/04/2026 -
electroCore Product Line Featured in Documentary Underscoring the Expanding Clinical and Commercial Role of Vagus Nerve Stimulation
23/04/2026 -
CytoDyn to Host Investor Webcast
23/04/2026 -
Jushi Holdings Inc. Applauds President Trump and Administration for Delivering on Cannabis Rescheduling to Schedule III under the Controlled Substances Act
23/04/2026 -
Belite Bio to Participate in Four Upcoming Investor Conferences
23/04/2026 -
Codexis to Report First Quarter 2026 Financial Results on May 7
23/04/2026 -
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
23/04/2026 -
Orion Group Interim report January–March 2026
23/04/2026 -
Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
23/04/2026
Pages